NXGL · XBRL financial data

NexGel financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NXGL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	2,048	4,089	8,688	11,421
Cost of revenue	965	1,542	1,792	3,470	5,940	6,912
Gross profit	(291)	9	256	619	2,748	4,509
Research and development	—	31	367	103	78	2
Selling, general and administrative	1,969	2,548	3,237	3,993	6,224	7,859
Total operating expenses	1,969	2,579	3,604	4,096	6,302	7,861
Operating income (loss)	(2,260)	(2,570)	(3,348)	(3,477)	(3,554)	(3,352)
Interest expense	—	—	1,336	15	81	34
Other income (expense)	(4)	(1,740)	—	—	—	—
Income tax expense (benefit)	0	0	0	—	—	—
Net income (loss)	(2,264)	(4,310)	(4,746)	(3,157)	(3,281)	(3,000)
Earnings per share, basic‡ USD per share	(1.03)	(1.45)	(0.85)	(0.56)	(0.50)	(0.38)
Earnings per share, diluted‡ USD per share	(1.03)	(1.45)	(0.85)	(0.56)	(0.50)	(0.38)
Weighted average shares, basic‡ thousands of shares	2,288	2,980	5,575	5,672	6,512	7,854
Weighted average shares, diluted‡ thousands of shares	2,288	2,980	5,575	5,672	6,512	7,854

‡ Per-share figures and share counts are adjusted for the 1-for-34.48275862068965 stock split (November 2021); filings made before it reported them unadjusted.

Fiscal years (NXGL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	32	13,350	1,101	2,700	1,807	317
Marketable securities	—	—	5,508	—	—	—
Accounts receivable	73	209	222	633	933	673
Inventory	233	291	502	1,319	1,751	2,111
Prepaid and other current assets	25	77	172	400	623	496
Total current assets	363	13,927	7,505	5,052	5,114	4,338
Property and equipment, net	553	723	721	1,499	2,211	1,955
Right-of-use asset	805	1,926	1,737	1,855	1,628	2,015
Goodwill	311	311	311	1,128	1,128	1,128
Total assets	2,257	16,983	10,357	9,955	10,983	10,461
Accounts payable	658	254	265	1,233	—	—
Total current liabilities	1,332	2,888	859	2,549	2,470	2,956
Lease liability, non-current	598	1,744	1,593	1,727	1,538	1,883
Total liabilities	2,186	4,898	2,720	4,789	4,903	5,570
Accumulated deficit	(2,502)	(6,812)	(11,558)	(14,715)	(17,996)	(20,996)
Total stockholders' equity	71	12,085	7,637	4,697	5,755	4,459
Total liabilities and equity	2,257	16,983	10,357	9,955	10,983	10,461
Common shares outstanding (cover page)‡ thousands of shares	2,984	5,572	5,611	6,228	7,654	8,476

‡ Per-share figures and share counts are adjusted for the 1-for-34.48275862068965 stock split (November 2021); filings made before it reported them unadjusted.

Fiscal years (NXGL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(2,264)	(4,310)	(4,746)	(3,157)	(3,281)	(3,000)
Stock-based compensation	232	285	298	217	367	654
Depreciation and amortization	50	113	112	226	436	450
Net cash from operating activities	(1,801)	(2,753)	(2,992)	(3,236)	(3,867)	(1,311)
Purchases of property and equipment	312	269	96	696	443	68
Net cash from investing activities	(312)	(269)	(5,595)	4,456	(775)	(68)
Proceeds from issuing common stock	1,370	13,471	—	—	—	—
Net cash from financing activities	1,884	16,340	(3,662)	379	3,749	630

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
CapsoVision	not reported	3,643	(8,403)*	50.0M	—	Q2 FY26 10-QJun 30, 2026
Guided Therapeutics	12	0	(319)*	96.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Mountain Crest Acquisition Corp. V	18	not reported	(79)*	2.9M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026
Co-Diagnostics	3,650	166	(7,153)*	6.3M	0.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.